Tag Archives: Others

China’s NHC Issues National Guidelines for Autism Intervention and Rehabilitation in Children – 2026 Edition Sets Standardized, Family‑Centered Care Framework Under the “Five‑Health” Action Plan

Beijing, China – 23 Sep 2026 – China’s National Health Commission (NHC) has released and published its official interpretation of the “Guidelines for Intervention and Rehabilitation of Children with Autism Spectrum Disorder (2026 Edition)” (《孤独症谱系障碍儿童干预康复指南(2026年版)》), the country’s standardized national playbook for screening‑linked intervention and rehabilitation services for children with autism spectrum disorder (ASD). The Guidelines were commissioned to advance implementation of the “Action Plan for Promoting the ‘Five Health’ of Children and Adolescents (2026–2030)” (儿童青少年”五健”促进行动计划) and to normalize ASD screening‑and‑intervention services nationwide.

Policy Snapshot

ItemDetail
Issuing BodyNational Health Commission of China (NHC), General Office
DocumentGuidelines for Intervention and Rehabilitation of Children with Autism Spectrum Disorder (2026 Edition) + official interpretation
Policy DriverImplementation of the “Five‑Health” Promotion Action Plan for Children and Adolescents (2026–2030)
ObjectiveStandardize ASD screening and intervention‑rehabilitation services for children
Clinical PremiseSpecific curative treatment for ASD etiology/pathogenesis remains limited; rehabilitation training is the primary intervention, with the optimal treatment window before age 6 — earlier intervention yields better outcomes
Structure6 parts: intervention goals, basic principles, intervention content, facilities & personnel, quality control, glossary + annexes
Effective TimelineNot disclosed

Guideline Framework – Six Core Components

  • Intervention Goals: Improve deficient behaviors; reduce non‑adaptive, non‑functional restricted interests and repetitive stereotyped behaviors; reduce and eliminate challenging behaviors; increase functional and adaptive behaviors; address coexisting problems and comorbidities; and enhance social adaptability and quality of life.
  • Basic Principles: Eight pillars — early intervention, individualized intervention, comprehensive intervention, scientific evidence‑based practice, long‑term high‑intensity programs, grassroots (primary‑care)‑led delivery, family participation, and social integration & support.
  • Intervention Content: Nine workstreams covering health education, intervention for deficient behaviors, intervention for non‑adaptive restricted interests/repetitive behaviors, challenging‑behavior intervention, coexisting problems and comorbidity management, family intervention, psychotherapy, digital‑intelligent (数智) intervention‑rehabilitation, and follow‑up care.
  • Facilities & Personnel: Standards defined across two dimensions — site conditions and staffing configuration for service delivery.
  • Quality Control: Multi‑tier oversight assigned to health administrative departments at all levels and to medical and health institutions delivering services.
  • Glossary & Annexes: Formal definitions for deficient behaviors, challenging behaviors, coexisting problems, comorbidities, individualized intervention‑rehabilitation plans, and family intervention; annexes detail age‑ and ability‑stratified intervention points, commonly used behavioral intervention strategies, challenging‑behavior management, and common coexisting‑problem interventions.

Clinical & Policy Context

  • Disease Profile: ASD is a neurodevelopmental disorder with onset in early childhood, characterized by impairments in social interaction and communication plus restricted interests and repetitive stereotyped behaviors. It typically follows a long‑term chronic course and may be accompanied by language delay, intellectual disability, self‑injurious and impulsive behaviors, and psychiatric or somatic comorbidities, causing varying degrees of impairment to social functioning and quality of life.
  • Early‑Window Emphasis: The interpretation reiterates that because specific etiology‑targeted therapies remain limited, rehabilitation training before age 6 is the decisive leverage point — a principle now embedded in national service standards.
  • Grassroots Delivery Model: The “primary‑care‑led” (基层为主) principle signals a policy shift of intervention capacity toward community and county‑level health institutions rather than concentrating care in tertiary hospitals.
  • Digital‑Intelligent Rehabilitation: The inclusion of 数智干预康复 (digital‑intelligent intervention) as one of nine content pillars formally recognizes technology‑assisted rehabilitation — a first‑class category in national ASD guidance.

Market Impact & Outlook

  • Service Standardization: The Guidelines establish the first unified national content, facility, staffing, and quality‑control specifications for pediatric ASD intervention‑rehabilitation, likely to shape provincial service catalogs, reimbursement discussions, and institutional accreditation.
  • Rehabilitation Sector Demand: Codifying “long‑term high‑intensity” and “family participation” principles points to sustained, multi‑year service demand for pediatric rehabilitation institutions, therapists, and training providers across the primary‑care network.
  • Digital Health Opportunity: Explicit endorsement of digital‑intelligent intervention opens a policy‑aligned lane for tele‑rehabilitation platforms, AI‑assisted assessment tools, and home‑based intervention software serving ASD families.
  • Diagnostics Linkage: Standardized screening‑intervention workflows under the “Five‑Health” plan should increase early identification rates, with downstream implications for developmental‑assessment services and related diagnostics.
  • Implementation Details Pending: Funding mechanisms, staffing quotas, and rollout timelines were not disclosed in the interpretation; provincial implementation plans are expected to follow.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding national implementation of China’s pediatric autism intervention guidelines, service capacity expansion, and digital‑health adoption. Actual outcomes may differ based on provincial execution, funding allocation, workforce availability, and subsequent policy issuances by the NHC and health authorities at all levels..-China Health Reform Pulse

Policy Source: https://www.nhc.gov.cn/fys/c100077/202609/4aa20e2af33d440880b485adcb8b33c3.shtml

China Launches Electronic Customs Clearance Pilot for Imported Drugs at Beijing Port – NMPA and GACC Grant Digital Documents Equal Legal Force

Beijing, China – 16 Sep 2026 – China’s National Medical Products Administration (NMPA) and the General Administration of Customs of China (GACC) jointly announced the launch of an electronic customs clearance pilot program for imported drugs (including medicinal crude materials) at Beijing Port, effective from the date of announcement. Under the pilot, electronic clearance documents carry the same legal force as their paper counterparts, marking a milestone in the digitization of China’s pharmaceutical import supervision.

Policy Snapshot

ItemDetail
Issuing AgenciesNMPA and General Administration of Customs of China (GACC)
Policy TypePilot program for electronic customs clearance documentation
ScopeImported drugs, including medicinal crude materials (药材)
Pilot LocationBeijing Port
Effective Date16 Sep 2026 (from date of announcement)
Legal StatusElectronic clearance documents have equal legal force with paper documents
Transition ArrangementPaper documents remain valid during the pilot; enterprises may continue using them per existing regulations
Expansion TimelineNot disclosed

Policy Details & Legal Framework

  • Objective: Further advance the digitalization of government services and improve the efficiency and convenience of customs clearance for imported drugs and medicinal materials.
  • Legal Parity: For the first time at the pilot port, electronic clearance documents are granted the same legal validity as paper documents — a critical enabler for fully digital cross-border pharmaceutical trade workflows.
  • Dual‑Track Transition: During the pilot period, the existing paper documentation remains valid, allowing importers to adopt the electronic channel at their own pace without operational disruption.
  • Joint Governance: The announcement was co‑issued by the drug regulator (NMPA) and the customs authority (GACC), reflecting cross‑agency coordination between product regulation and border control in pharmaceutical imports.

Industry Context

  • Legacy Paper Burden: Pharmaceutical imports into China have traditionally required paper‑based clearance certificates at ports of entry, adding administrative steps and courier logistics to time‑sensitive shipments.
  • Digital Trade Facilitation: The pilot aligns with China’s broader push to digitize government services and cross‑border trade documentation, including electronic customs declaration and paperless clearance reforms.
  • Inclusive Scope: By explicitly covering medicinal crude materials (药材) alongside finished drugs, the pilot addresses a segment historically subject to specialized port inspection requirements.
  • Strategic Entry Point: Beijing Port — served by Capital International Airport and Daxing International Airport cargo facilities — is a key gateway for imported pharmaceuticals, biologics, and temperature‑sensitive products.

Market Impact & Outlook

  • For Importers: Multinational pharmaceutical companies, distributors, and trading firms importing finished drugs, APIs, and herbal materials through Beijing can expect streamlined clearance procedures and reduced paperwork, lowering administrative costs.
  • Supply Chain Resilience: Electronic documentation reduces dependence on physical transport of clearance certificates, benefiting cold‑chain and urgent humanitarian shipments.
  • Regulatory Signal: The pilot may serve as a template for broader rollout to other major ports should it prove successful; no expansion timeline or additional ports have been disclosed.
  • Compliance Note: Enterprises operating dual‑track documentation should ensure internal systems can reconcile electronic and paper records during the transition period.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory implementation timelines, pilot expansion, and operational expectations for electronic customs clearance of imported drugs in China. Actual outcomes may differ due to factors including administrative execution at port level, enterprise adoption rates, and subsequent policy adjustments by the NMPA and GACC..-China Health Reform Pulse

Policy Source: https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20260921091608111.html

Yunnan Reclassifies Five Listed Drugs as Essential Medicines – Commitment‑Based Filing Opens as Attribute Changes Take Effect

Kunming, China – 20 Sep 2026 – The Yunnan Provincial Government Procurement and Transfer Center publicized a batch of drug attribute changes on the provincial procurement platform, reclassifying five products from non‑essential‑drug status to essential drug (including former provincial‑supplement items) under the National Essential Medicines List (2026 Edition) and the Yunnan Provincial Supplemental Drug Catalog. Affected manufacturers must complete notification‑and‑commitment filing with the Yunnan Provincial Medical Products Administration (MPA) effective immediately, while objections must be lodged within five working days of the publicity date.

Policy Snapshot

ItemDetail
AgencyYunnan Provincial Government Procurement and Transfer Center
DocumentPublicity of Drug Attribute Changes for Platform‑Traded Products (annexed Attribute Change Table)
BasisNational Essential Medicines List (2026 Edition); Yunnan Provincial Supplemental Drug Catalog
Products Affected5 – all reclassified from non‑essential drug to essential drug / former provincial supplement
Price & Registration ImpactApproval numbers unchanged; procurement price ceilings unchanged
Filing ObligationNotification‑and‑commitment filing with Yunnan MPA, effective from the publicity date
Objection Window5 working days from publicity (enterprises: 0871‑63606934, Drug & Device Procurement Section; public: 0871‑65330065, Comprehensive Supervision Section)
Filing VenueReception Hall, 1F, Yunnan Institute for Food and Drug Control and Testing – New Building, 616 Kefa Road, Kunming; Tel: 0871‑63112057

Products Reclassified

Product IDGeneric NameDosage FormSpecificationManufacturer / BidderNew Attribute
53521224Cefradine for InjectionInjection1.0 g (as C16H19N3O4S)Shaanxi Dunsi Pharmaceutical Co., Ltd.Former provincial supplement
53527176Inosine InjectionInjection2 ml : 0.1 gShaanxi Dunsi Pharmaceutical Co., Ltd. / Xi’an Tangchen Pharmaceutical Co., Ltd. (bidder)Former provincial supplement
53526685Pancreatin Enteric‑Coated TabletsEnteric‑coated tablet0.3 g × 24 tablets/boxChongqing Tianzhi Pharmaceutical Co., Ltd.Essential drug (NEML 2026)
53825865Pancreatin Enteric‑Coated TabletsEnteric‑coated tablet0.3 g × 48 tablets/boxChongqing Tianzhi Pharmaceutical Co., Ltd.Essential drug (NEML 2026)
53501920Longbishu TabletsSugar‑coated tablet0.3 g core weight × 18 tablets/boxQinhuangdao Da’en Pharmaceutical Co., Ltd.Essential drug (NEML 2026)

Compliance Obligations & Procedure

  • Notification‑and‑Commitment Filing: For products flagged “essential drug (incl. former provincial supplement)”, the filing process opens immediately. Enterprises must follow the requirements set out in the Yunnan MPA’s published announcement (mpa.yn.gov.cn, notice t20210917_1231876) and complete commitment‑based filing in person, bringing a printed copy of this publicity notice to the designated Yunnan MPA location.
  • Consequences of Non‑Filing: Enterprises that fail to complete the notification‑and‑commitment filing bear full responsibility for the consequences, per the notice – a clear signal that platform trading status may hinge on timely compliance.
  • Dual‑Track Objection Mechanism: Applicant enterprises with queries on the publicized information contact the Center’s Drug & Device Procurement Section (0871‑63606934); other enterprises or members of the public raising objections contact the Comprehensive Supervision Section (0871‑65330065) – both within five working days of the publicity date, with the publicized content open to general supervision.
  • Administrative Continuity: Because drug approval numbers and procurement price ceilings remain unchanged, the reclassification is an attribute‑level adjustment rather than a repricing event – preserving existing commercial terms while altering catalog status.

Market Impact & Outlook

  • NEML 2026 Alignment: Three of the five products (both Pancreatin SKUs and Longbishu Tablets) were upgraded directly under the National Essential Medicines List (2026 Edition), illustrating how provinces are synchronizing procurement‑platform attributes with the refreshed national catalog.
  • Essential‑Drug Advantage: Essential‑drug designation typically carries policy preference in procurement and clinical use at public medical institutions – a status upgrade that can broaden access for the affected manufacturers’ products in Yunnan.
  • Provincial‑Supplement Track: The two former provincial‑supplement items (Cefradine for Injection, Inosine Injection) reflect continued recognition of Yunnan’s supplemental catalog alongside the national list, per the notice’s stated basis.
  • Tight Compliance Clock: With filing open “effective immediately” and only five working days to lodge objections, manufacturers must act within the same week to secure catalog status and avoid jeopardizing platform trading eligibility.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding filing outcomes, objection handling, catalog status, and platform trading eligibility for the five reclassified drug products in Yunnan Province. Actual results may differ due to risks including filing completion status, objection decisions, and subsequent policy adjustments by the Yunnan Provincial Government Procurement and Transfer Center and the Yunnan Provincial Medical Products Administration.-China Health Reform Pulse

Policy Source: http://www.ynyyzb.com.cn/detail.html?infoId=27877&CatalogId=3